Proportion of patients reaching each category of different response and remission criteria after 3–4 months of methotrexate monotherapy
| Overall (n=395) | In model (n=322) | |||
|---|---|---|---|---|
| EULAR response* | ||||
| Good, n (%) | 136 | 34% | 94 | 29% |
| Moderate, n (%) | 161 | 41% | 142 | 44% |
| None, n (%) | 98 | 25% | 86 | 27% |
| ACR response† | ||||
| ACR70, n (%) | 53 | 13% | 38 | 12% |
| ACR50, n (%) | 131 | 33% | 97 | 30% |
| ACR20, n (%) | 213 | 54% | 161 | 50% |
| SDAI response‡ | ||||
| Major, n (%) | 134 | 33% | 105 | 33% |
| Minor, n (%) | 143 | 35% | 117 | 36% |
| None, n (%) | 128 | 32% | 100 | 31% |
| CDAI response§ | ||||
| Major, n (%) | 213 | 53% | 169 | 53% |
| Minor, n (%) | 89 | 22% | 72 | 22% |
| None, n (%) | 102 | 25% | 80 | 25% |
| DAS28 remission | 90 | 22% | 58 | 18% |
| SDAI remission‡ | 53 | 13% | 35 | 11% |
| CDAI remission§ | 59 | 15% | 39 | 12% |
Definitions of the outcome measures are given in table 1 in the online supplement.
↵* EULAR (EUropean League Against Rheumatism) response.
↵† ACR (American College of Rheumatology) response criteria.
↵‡ SDAI (Simple Disease Activity Index) response/remission.
↵§ CDAI (Clinical Disease Activity Index) response/remission.
DAS28, 28-joint Disease Activity Score.